Mersana Therapeutics Inc (NASDAQ: MRSN) is 147.84% higher on its value in year-to-date trading and has touched a low of $0.80 and a high of $9.62 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MRSN stock was last observed hovering at around $5.94 in the last trading session, with the day’s loss setting it -0.19%.
Currently trading at $5.75, the stock is 42.16% and 77.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.22 million and changing -3.20% at the moment leaves the stock 101.04% off its SMA200. MRSN registered 1.23% gain for a year compared to 6-month gain of 418.02%. The firm has a 50-day simple moving average (SMA 50) of $14.73 and a 200-day simple moving average (SMA200) of -$3.27.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 70.12% loss in the last 1 month and extending the period to 3 months gives it a 248.48%, and is 41.63% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.22% over the week and 11.09% over the month.
Mersana Therapeutics Inc (MRSN) has around 123 employees, a market worth around $697.48M and $36.85M in sales. Profit margin for the company is -465.80%. Distance from 52-week low is 617.49% and -40.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-263.08%).
Mersana Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $8.5M over the same period.The EPS is expected to grow by 55.58% this year, but quarterly earnings will post 6.00% year-over-year. Quarterly sales are estimated to grow 8.90% in year-over-year returns.
Mersana Therapeutics Inc (MRSN) Top Institutional Holders
150 institutions hold shares in Mersana Therapeutics Inc (MRSN), with institutional investors hold 97.11% of the company’s shares. The shares outstanding are 120.71M, and float is at 91.80M with Short Float at 7.73%. Institutions hold 95.89% of the Float.
The top institutional shareholder in the company is Bain Capital Life Sciences Investors, LLC with over 8.66 million shares valued at $28.5 million. The investor’s holdings represent 7.19% of the MRSN Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 7.96 million shares valued at $26.2 million to account for 6.61% of the shares outstanding. The other top investors are Orbimed Advisors LLC. which holds 7.21 million shares representing 5.99% and valued at over $23.74 million, while Avoro Capital Advisors LLC holds 5.29% of the shares totaling 6.38 million with a market value of $20.97 million.
Mersana Therapeutics Inc (MRSN) Insider Activity
A total of 5 insider transactions have happened at Mersana Therapeutics Inc (MRSN) in the last six months, with sales accounting for 1 and purchases happening 4 times. The most recent transaction is an insider sale by Protopapas Anna,the company’sDirector. SEC filings show that Protopapas Anna sold 29,399 shares of the company’s common stock on Jan 16 at a price of $2.71 per share for a total of $79671.0. Following the sale, the insider now owns 0.13 million shares.
Mersana Therapeutics Inc disclosed in a document filed with the SEC on Jan 16 that Lowinger Timothy B (SVP, Chief Sci.&Tech. Officer) sold a total of 10,409 shares of the company’s common stock. The trade occurred on Jan 16 and was made at $2.71 per share for $28208.0. Following the transaction, the insider now directly holds 0.2 million shares of the MRSN stock.
Still, SEC filings show that on Jan 16, DeSchuytner Brian (SVP, COO & CFO) disposed off 9,327 shares at an average price of $2.71 for $25276.0. The insider now directly holds 54,511 shares of Mersana Therapeutics Inc (MRSN).
Mersana Therapeutics Inc (MRSN): Who are the competitors?
The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading 14.02% up over the past 12 months. Roche Holding AG Akt (RO) that is -14.09% lower over the same period.
